Double Marker Test in Pregnancy: What It Screens For, How to Read the Report, and What It Cannot Tell You

Key takeaways

• The double marker test is a screening test, not a diagnosis, it produces a probability, never a yes or no.
• The double marker test performs best as part of the combined first-trimester screen, alongside a nuchal translucency ultrasound and precise dating.
• A "low risk" result lowers the chance of the screened trisomies but does not exclude them, and says nothing about most other genetic or structural conditions.
• A "high risk" result is not a diagnosis. Most women with a high-risk screen go on to have a baby without the screened condition.
• In India, all prenatal ultrasound, including the nuchal translucency scan, is governed by the PC-PNDT Act, 1994. Sex determination is a criminal offence and is never disclosed.

At a glance

Also known as

• Dual marker test
• First trimester screening blood test
• Combined first-trimester screening (when reported with the NT scan)
• PAPP-A and free beta-hCG test
• Commonly called the "double marker" or "first trimester screening" in Indian obstetric practice; the paired scan is called the "NT scan", "sonography" or "USG"

What the double marker test is

The double marker test measures two substances produced in pregnancy:

• Free beta-hCG: a fraction of human chorionic gonadotropin made by the placenta.
• PAPP-A (pregnancy-associated plasma protein-A): a placental protein.

Neither marker is measured to see whether it is "normal" on its own. The laboratory converts each value into a MoM (multiple of the median) adjusted for gestational age, maternal weight, ethnicity, smoking, diabetes status, IVF conception and multiple pregnancy. Software then combines the MoMs with maternal age and, where available, the nuchal translucency measurement and maternal heart rate, to generate a single risk figure for each condition screened.

Broadly, pregnancies affected by trisomy 21 tend to show lower PAPP-A and higher free beta-hCG, while trisomy 18 and 13 tend to show both markers low. These are population tendencies with wide overlap, an individual value tells you very little by itself.

Why the double marker test is done

• To estimate, early in pregnancy, the chance that the baby has trisomy 21, 18 or 13.
• To help you and your obstetrician decide whether further testing, NIPT, CVS or amniocentesis, is worth considering.
• To allow time for counselling, planning of delivery location, and paediatric input if a condition is later confirmed.
• Low PAPP-A is also associated with an increased chance of placental problems later in pregnancy, such as growth restriction or pre-eclampsia, so some units use it to guide surveillance. This is an association, not a prediction.

Who should consider the double marker test

Screening for chromosomal conditions is offered to all pregnant women in the first trimester, regardless of age or risk. It is a choice, not a requirement, declining screening is a valid decision.

• All pregnancies: first-trimester combined screening is routinely offered in most Indian obstetric units.
• Maternal age 35 years and above: baseline chance of trisomy rises with age, so screening is often actively discussed.
• Previous pregnancy affected by a chromosomal condition: such women usually need specialist genetic counselling in addition to, or instead of, standard screening.
• Family history of chromosomal or genetic conditions: a double marker test may be inadequate; referral for genetic counselling is appropriate.
• Women who want information but wish to avoid invasive testing initially: screening gives a risk estimate without any procedure-related pregnancy loss risk.

The double marker test is less informative, or reported differently, in twin and higher-order pregnancies and after a vanishing twin. Discuss this with your obstetrician before booking.

What the double marker test cannot detect or exclude

This is the part most often misunderstood, so it is set out plainly.

• The double marker test cannot diagnose anything. It gives a probability. Only a chromosomal analysis from CVS or amniocentesis can confirm or exclude a trisomy.
• A low-risk result does not exclude Down syndrome, Edwards syndrome or Patau syndrome. Screening misses a proportion of affected pregnancies. "Not identified as high risk" is not the same as "does not have the condition".
• The test does not screen for most genetic conditions. Thalassaemia, sickle cell disease, cystic fibrosis, spinal muscular atrophy, fragile X and single-gene disorders are not assessed.
• The test does not detect structural birth defects. Heart defects, cleft lip and palate, limb anomalies and most brain anomalies require the anomaly scan at around 18-22 weeks and, where indicated, fetal echocardiography.
• The test does not screen for neural tube defects such as spina bifida. That is assessed by ultrasound and, in some protocols, second-trimester AFP.
• The test does not assess autism, intellectual disability of unknown cause, or developmental outcome.
• The test does not tell you the baby's sex, and in India sex determination or disclosure is prohibited by law.
• The test cannot compensate for uncertain dates. If gestational age is wrong, the risk calculation is wrong.

If a problem is suspected clinically at any stage despite a low-risk double marker result, go back to your obstetrician. A reassuring screen does not close the question.

Related but different examinations

These tests answer different questions. None is universally "better". Which is appropriate depends on your gestational age, your prior risk, availability and cost, and what you would do with the information.

How to prepare

Preparation is minimal, but the accuracy of the calculation depends heavily on the information you supply.

• Timing: book within the window your obstetric unit specifies. Protocols differ between hospitals and laboratories, and your unit's instructions take precedence over anything written here.
• Fasting: fasting is generally not required for the double marker test. If your unit asks you to fast for other tests drawn at the same time, follow their instruction.
• Dating: carry your dating scan report. The crown-rump length measurement is essential to the calculation.
• Details to declare: your exact weight on the day, ethnicity, smoking status, diabetes and its treatment, IVF or donor-egg conception, twin pregnancy or vanishing twin, and any previous affected pregnancy. Omitting any of these can shift the reported risk.
• Medication: tell the requesting doctor everything you take, including AYUSH, herbal and over-the-counter preparations. Do not stop or change any prescribed medicine on your own, speak to the prescriber.
• Counselling first: ideally discuss with your obstetrician what you would do with a high-risk result before the sample is taken.

If you have diabetes on glucose-lowering treatment

Do not skip meals or omit insulin or tablets for this test unless your diabetes team has told you to. There is no routine fasting requirement. Pre-existing diabetes is a correction factor in the risk software and must be declared.

If you are carrying twins or more

Risk calculation in multiple pregnancy is less reliable, differs between chorionicity types, and is often reported per pregnancy rather than per fetus. Some units prefer NT-based assessment. Discuss this in advance.

If the pregnancy followed IVF or egg donation

Gestational age is calculated from the embryo transfer date, and donor-oocyte age rather than your own age may be used. Tell the laboratory, this materially changes the result.

If you have a bleeding disorder or take anticoagulants

Tell the phlebotomist. Pressure is applied for longer after the draw. Do not alter anticoagulant dosing yourself.

What happens during the double marker test

• Registration and history: your dates, weight and relevant history are recorded. This takes a few minutes and matters as much as the blood itself.
• Blood draw: a few millilitres of blood are taken from a vein in the arm. The draw itself takes under a minute; expect 5-10 minutes in the room.
• NT ultrasound, if scheduled: a transabdominal scan, occasionally transvaginal if views are poor. Typically 20-30 minutes, sometimes longer if the baby is not in a suitable position and you are asked to walk about and return.
• Afterwards: no recovery time is needed. You can eat, drive and work as usual.
• Reporting: the laboratory runs the assay and enters your data into risk-calculation software. Reporting time varies between laboratories, ask your unit when you book.

Understanding your double marker report

A double marker report usually contains three layers of information.

• Raw concentrations of free beta-hCG and PAPP-A, in IU/L or ng/mL. These are not interpreted directly by patients or, usually, by clinicians.
• MoM values: each marker expressed as a multiple of the median for your gestational age after adjustments. A MoM near 1.0 means the value sits close to the typical level for that stage.
• Risk ratios: expressed as, for example, 1 in 120 or 1 in 4,500, for each condition screened, often with both an age-related background risk and an adjusted risk.

How to read a risk ratio: 1 in 4,500 means that of 4,500 women with this exact result, about one would have an affected baby. A larger second number means a lower chance. 1 in 100 is a higher risk than 1 in 1,000, even though 1,000 is the bigger number, this is the single most common misreading.

"Screen positive" and "screen negative": laboratories apply a cut-off to divide results into increased-risk and low-risk categories. The cut-off used varies between laboratories and protocols, so the same numbers can be labelled differently in different reports. A screen-positive result is not a diagnosis, and most screen-positive pregnancies turn out to be unaffected. A screen-negative result lowers but does not remove the chance of the screened conditions.

Do not interpret the report alone. Ask the obstetrician who requested the double marker test to explain the numbers in the context of your age, history and scan findings. Results vary depending on individual clinical circumstances.

When double marker results can be misleading

Factors that can falsely raise the calculated risk

• Underestimated gestational age: if the pregnancy is more advanced than recorded, marker MoMs are misassigned and risk can be inflated.
• Weight recorded incorrectly or not recorded, maternal weight adjusts marker concentrations.
• Undeclared twin pregnancy or a vanishing twin, which distorts both markers.
• Undeclared IVF conception, which alters typical marker distributions.
• Placental conditions unrelated to chromosomes, which can lower PAPP-A and push the risk figure up even though the chromosomes are normal.
• Advanced maternal age alone can drive a screen-positive result even with entirely typical marker levels, because age is part of the calculation.

Factors that can falsely lower the calculated risk

• Overestimated gestational age or use of last menstrual period dating when cycles are irregular.
• Testing outside the validated window, where marker performance is poorer.
• A technically suboptimal NT measurement that under-reads the true value.
• Inherent test limitation: a proportion of affected pregnancies simply have marker levels in the ordinary range. This is why a low-risk result is reassurance, not proof.

Situations where the result may not be valid at all

• Sample taken before or after the laboratory's validated gestational window.
• Haemolysed or delayed sample.
• Higher-order multiple pregnancy.
• Missing dating scan, so gestational age is uncertain.

Risks and safety

The blood test component

Taking blood from a vein carries the usual minor risks: brief pain, bruising, light-headedness, and rarely a small haematoma or local infection. There is no direct risk to the pregnancy from the blood draw.

The nuchal translucency ultrasound component

Diagnostic ultrasound uses sound waves, not ionising radiation, and is considered safe when used for a clinical indication by a trained operator. Scans should be performed only when clinically indicated. Transvaginal scanning, if required, may be briefly uncomfortable.

Psychological and decisional risks

These are the most substantial risks of screening and are frequently understated. A screen-positive result causes significant anxiety, and most such pregnancies are unaffected. It may lead to invasive testing, which carries a small procedure-related pregnancy loss risk. A screen-negative result can also create false reassurance. Pre-test counselling reduces, but does not remove, these harms. Results vary depending on individual clinical circumstances.

Special situations

Women aged 35 and over

Background risk of trisomy rises with maternal age, so age alone can produce a screen-positive result. Many such women are offered NIPT or a direct discussion about diagnostic testing rather than relying on the double marker test alone.

Twin and higher-order pregnancies

Marker interpretation is less reliable. NT measurement of each fetus often carries more weight. NIPT performance also differs in twins. Specialist input is advisable.

Pregnancy with pre-existing diabetes

Insulin-treated diabetes is applied as a correction factor by most laboratories. Declare it. Do not alter diabetes medication for the test.

Women with thalassaemia trait or haemoglobinopathies

Haemoglobinopathy status does not affect double marker performance, but it is a separate and important issue in India. Beta-thalassaemia trait is common in several Indian communities. Carrier screening of both partners, and prenatal diagnosis where both are carriers, is a distinct pathway from the double marker test and is not covered by it.

Women who conceived through IVF or donor eggs

Gestational dating from transfer date and the correct oocyte age must be entered. Failing to do so can substantially misstate the risk.

Women who present late

If you present beyond the first-trimester window, the double marker test is no longer appropriate. Second-trimester quadruple marker screening, NIPT or a detailed anomaly scan may be offered instead.

The double marker test in the Indian context

• PC-PNDT Act, 1994: all prenatal diagnostic procedures, including the NT scan and any genetic test, are regulated. Determination or communication of fetal sex is a criminal offence. Registered centres display this, and you will be asked to sign Form F before an obstetric ultrasound. No clinician, sonologist or laboratory will disclose the baby's sex, and you should not ask.
• MTP Act context: decisions after a confirmed diagnosis are governed by the Medical Termination of Pregnancy Act as amended in 2021, including provisions relating to substantial fetal abnormality and Medical Boards. Your obstetrician will explain what applies to your gestation and circumstances.
• Access and quality: the accuracy of combined screening depends on an NT measurement taken by an operator with appropriate training and audited technique. Availability of such operators varies considerably between cities and smaller towns. Ask whether the NT will be performed to a recognised standard.
• Terminology: the NT scan is commonly called "sonography" or "USG"; the blood test is often simply called "double marker" at the counter.
• Genetic counselling capacity is limited outside major centres. If your result is screen positive, ask specifically for a referral rather than making decisions from a report alone.

Cost and insurance in India

Prices differ widely between cities, between government and private facilities, and between laboratories. Ask for a written quotation before booking.

Factors that influence what you pay:

• Whether the double marker blood test is billed alone or as a combined first-trimester screening package with the NT scan.
• The risk-calculation software and accreditation standard used by the laboratory.
• City tier and whether the facility is a standalone laboratory, a diagnostic chain or a hospital.
• Whether a consultation, genetic counselling or repeat scan is required.
• Whether the alternative chosen is NIPT, which typically costs many times more than the double marker test.
• Government and public-sector maternity programmes may provide antenatal screening at subsidised or no cost in some states.

Insurance: routine antenatal outpatient screening is often not covered by standard Indian health insurance policies, which frequently exclude outpatient diagnostics and may apply maternity waiting periods. Some corporate and maternity-benefit policies do cover antenatal investigations. Check your policy wording and pre-authorisation rules with your insurer before the test. Any cost figures quoted anywhere are indicative only and are not a quotation.

Myths and facts

Frequently asked questions

Is the double marker test compulsory in pregnancy?

No. The double marker test is offered, not mandated. Some women want the information, others prefer not to screen. Declining is a legitimate choice and does not affect the rest of your antenatal care. Discuss with your obstetrician what you would do with each possible result before deciding.

How long does the double marker test take?

The blood draw itself takes under a minute, with about 5-10 minutes in the room including registration. If a nuchal translucency scan is done at the same visit, allow a further 20-30 minutes, occasionally longer if the baby is poorly positioned. Reporting time varies between laboratories.

What is the difference between the double marker and triple marker test?

The double marker test is a first-trimester blood test measuring free beta-hCG and PAPP-A. The triple or quadruple marker test is performed in the second trimester with different markers and additionally screens for open neural tube defects. They are alternatives used at different stages, not sequential confirmations.

Should I choose NIPT instead of the double marker test?

NIPT detects the common trisomies more sensitively but remains a screening test requiring confirmation if positive, and costs considerably more. NIPT also does not replace the nuchal translucency scan, which contributes structural information. The right choice depends on your risk, budget and what you would do with the result.

My PAPP-A is low but the risk is low. Should I worry?

Low PAPP-A with a low overall risk usually means the chromosomes are unlikely to be affected. However, low PAPP-A is associated with a higher chance of placental problems such as growth restriction or pre-eclampsia. Your obstetrician may recommend additional growth scans or blood pressure monitoring.

Can the double marker test be done after 14 weeks?

Generally not. The markers and the nuchal translucency measurement are only valid within a defined first-trimester window, which your unit will specify. If you present later, second-trimester quadruple marker screening, NIPT or a detailed anomaly scan may be offered instead.

Does a normal NT scan mean I can skip the blood test?

No. Nuchal translucency and the serum markers contribute independently to the risk calculation. Combined screening performs better than either component alone. A normal NT measurement on its own does not exclude a chromosomal condition.

What happens if my result is screen positive?

You should be offered counselling to explain the numbers, and a discussion about options: NIPT as a more sensitive second screen, or CVS or amniocentesis for a definitive answer. Invasive tests carry a small procedure-related pregnancy loss risk. Choosing no further testing is also a valid option.

Will the test tell me if my baby has a heart defect?

No. The double marker blood test does not assess structure. Increased nuchal translucency on the accompanying scan can prompt fetal echocardiography, but cardiac anomalies are chiefly looked for at the anomaly scan around 18-22 weeks and on specialist fetal echo where indicated.

Sources

• Pre-conception and Pre-natal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994, Government of India.
• Medical Termination of Pregnancy (Amendment) Act, 2021, Government of India.
• Federation of Obstetric and Gynaecological Societies of India (FOGSI), Good Clinical Practice Recommendations on prenatal screening.
• International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) Practice Guidelines, first-trimester fetal ultrasound.
• American College of Obstetricians and Gynecologists, Screening for Fetal Chromosomal Abnormalities, Practice Bulletin.
• Royal College of Obstetricians and Gynaecologists / UK NHS Fetal Anomaly Screening Programme, combined test handbook.